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Background: Globally, new HIV-infections continue to occur mostly in Sub-Saharan Africa 
despite the known-to-work HIV-prevention interventions. Suboptimal adherence to the available 
HIV prevention interventions is cited. Vaccination could help minimise non-adherence to an HIV 
preventive intervention but does require the completion of the full vaccination schedule. An HIV 
vaccine would be a useful addition to HIV prevention packages, but vaccines need assessment in 
efficacy trials and investigators need suitable populations for trials. Key populations including 
Fisher-folks (FF) and Female Sex Workers (FSW) in Uganda could be useful. However, available 
data for planning trials in these populations come from observational cohorts and evidence 
suggests that trial environment and/or participants selection could differ from observational 
cohorts, which could alter trial targeted outcomes. This difference was investigated using 
Simulated HIV-vaccine efficacy trials (SiVETs); a trial that mimicked an HIV vaccine efficacy 
trial using a proxy vaccine.  
Methods:  Two SiVETs were nested within observational cohorts of FF (2012 – 2014) and FSW 
(2014-2017). The SiVETs screened and enrolled participants from observational cohorts, and 
administered a licensed Hepatitis B vaccine at 0, 1 and 6 months as a proxy for an HIV-vaccine. 
Over the 12 month follow-up, SiVETs conducted HIV testing, risk behaviour assessment, and 
promoted and provided reliable contraceptives to women. 
Results: In total, there were 3989 [1575 FF & 2414 FSW] participants in the observational cohorts 
and 572 [282 FF & 290 FSW] of these were enrolled into SiVETs. There were significant 
differences between characteristics of participants in SiVETs and those in the observational 
cohorts. At 12-months, HIV incidence and risk behaviours were higher in the observational cohorts 
than SiVETs while retention was lower. Promotion and provision of reliable contraceptives in 
SiVETs increased the proportion of women using them from 55% at baseline to >90% at the end 
of vaccination.  
Conclusion: Researchers designing HIV efficacy trials using observational data in these and 
similar populations need to consider potential for changes in the targeted trial outcomes following 
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Chapter one: Background  
1.1 Global HIV burden  
The burden of HIV continues to be a global challenge 38 years after diagnosis of the first case of 
HIV/AIDS (1).  According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) 2019 
report, Sub Saharan Africa (SSA) is disproportionately affected (2). The report estimates that in 
2018, 61% of global new HIV infections happened in SSA (2). In SSA, the new HIV infections 
vary by region with Eastern and Southern Africa accounting for most of these (2). The new 
infections are happening, despite the potential to curb them with effective biomedical HIV 
prevention interventions, including safe medical male circumcision (3, 4), antiretroviral therapy 
(ART) in form of Pre Exposure Prophylaxis (PrEP) (5-9) or treatment of the HIV infected partner 
to prevent transmission (10). Suboptimal adherence to available interventions has been identified 
as the key challenge in fighting against HIV infection in SSA (5).  
1.2 Need for HIV vaccine   
One of the long-term hopes for controlling the HIV/AIDS pandemic is a safe, effective and 
affordable preventive HIV vaccine (11-13).  Historically, vaccines have been more effective than 
therapeutic medicines at curbing infectious diseases (14). Even in countries with limited resources, 
comprehensive national immunization programmes have led to eradication or reduction of 
smallpox, polio, measles, pertussis, meningococcal meningitis, diphtheria, hepatitis B, congenital 
rubella syndrome, and tetanus among other infectious diseases (15). Furthermore, vaccines have a 
unique public health importance through herd immunity (16-18) and are likely to reduce the burden 
of adherence compared to a daily pill (13).    
1.2.1 Populations for HIV vaccine efficacy trials  
The HIV vaccines in development have to go through rigorous assessment in efficacy trials. 
Therefore, populations with high HIV incidence, good retention in follow up and adequate access 
to and use of HIV related health services are needed to conduct successful HIV vaccine efficacy 
trials (19). Because of the high HIV incidence, SSA is likely to continue being a major destination 
for HIV prevention trials. However, in countries such as Uganda where the general population 
HIV prevalence is high > 7% (20, 21) but annual incidence low < 1% (20, 22, 23), HIV vaccine 
efficacy trials will have to be conducted among population subgroups. The subgroups could 
include HIV discordant couples, occupational women at high risk of HIV acquisition- Female Sex 
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Workers (FSW), members of the fishing communities-Fisher-folks (FF) on the shore of Lake 
Victoria and men who have sex with men (MSM). Observational cohorts conducted in these 
population subgroups have shown that, they are characterized by high HIV incidence, 3.4 to 11.4 
new cases per 100 person years (24-30), high willingness to participate, > 89% (31, 32) and good 
retention in follow up, >75% (28, 33, 34). 
Recent findings in HIV discordant couples confirmed that, ART significantly reduces the risk of 
HIV transmission from an infected to an uninfected partner (35). With evidence that 
Undetectable=Untransmissable (36), HIV vaccine efficacy trials conducted in discordant couples 
with a high use of ART may have lower HIV incidence, perhaps even low enough to undermine 
use of these populations for potential HIV vaccine efficacy trials. In Uganda, there is limited or no 
data on MSM and this population remains challenging to work with for a myriad of legal and 
related reasons (37). Therefore, occupational women in sex work (FSW) and members of fishing 
communities on the shoreline of Lake Victoria remain the only potential key populations eligible 
for HIV vaccine efficacy trials in Uganda.  
1.2.2 Designing HIV efficacy trials in these Key populations 
Designing HIV vaccine efficacy trials in the FSW and FF populations in Uganda requires accurate 
estimation of the expected HIV incidence in the control (placebo) arm, routine use of reliable 
contraceptives by female participants to prevent pregnancy, good retention in follow up and 
provision of other HIV risk reduction measures such as routine HIV counselling among others. 
The common practice includes obtaining estimates from previous efficacy trials in the same or 
similar population. To our knowledge, no HIV efficacy trials have completed follow up in the FF 
on the shoreline of Lake Victoria in Masaka or FSW in Kampala to provide this baseline data and 
key populations tend to be different from the general population.   
In the absence of previous trials, data from historical observational cohorts, pilot cohorts and/or 
studies of willingness to participate may be used. One of the challenges in designing HIV 
prevention trials is that observational data in the target population is often very different from that 
found in a trial. While the efficacy trial environment is highly controlled with participants visiting 
study clinic more frequently for HIV risk reduction counselling, provision of condoms and 
treatment of other sexually transmitted infections, this might not be the case in observational 
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cohorts. The differences in procedures between efficacy trials and observational cohort could alter 
the efficacy trial control arm HIV incidence obtained from the underlying population observational 
cohort and used to plan efficacy trials, as seen previously (38, 39).  If not carefully considered, this 
could lead to failure to calculate a proper trial sample size.  
In light of lack of previous trials in the FF on the shore of Lake Victoria and FSW in Kampala 
Uganda, what may not be answered for these key populations is the effect of selection into trial on 
underlying population HIV incidence. Trial selection criteria include participants that accept  to 
delay pregnancy through routine use of reliable contraceptives, keep in follow up for the trial 
duration and positively respond to HIV risk reduction measures provided in trials. These could 
alter HIV incidence and hence trial statistical power as previously highlighted in other trials, 
elaborated below.     
1.3 Trial targeted outcome and other elements for planning trials 
1.3.1 HIV incidence  
The trial inclusion criteria select participants whose characteristics are different from those not 
selected from the source population (26, 40). Participants that consider themselves at high risk of 
HIV infection participate more in feasibility cohorts than clinical trials (40). This difference and/or 
trial controlled environment could in some way bias/diminish HIV incidence in the trial even in 
absence of an effective new HIV biomedical intervention. The lower HIV incidence in the control 
arm than that predicted at the trial design could affect the trial statistical power.   
One systematic review (41) identified six HIV prevention studies that were unsuccessful or 
terminated because of reduced statistical power, due to observing lower HIV incidence during 
participant follow up than that predicted based on the source population observational data. Similar 
loss in statistical power was observed in 2007/8 in microbicides trials in Nigeria (38) and Ghana 
(39, 42). A similar reason led to premature termination of these trials. In the three trials, HIV 
incidence of 5 per 100 person years at risk (PYAR) had been predicted at the design stage but the 
investigators only observed HIV incidence of 1.5 per 100 PYAR  (38), 1.1 per 100 PYAR (39) 
and 2.5 per 100 PYAR (42) in the control arms during participant follow up.  
On the contrary, a more recent trial in South Africa in 2016 (43) had the sample size recalculated 
to a lower number after observing more than anticipated HIV incidence. In this trial, HIV incidence 
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of 3.9 per 100 PYAR had been predicted and used to determine the trial size at the design stage 
but the sample size was adjusted (on recommendation of independent data monitoring committee) 
basing on HIV incidence of 5 per 100 PYAR observed during follow up. At trial completion, the 
investigators observed HIV incidence of 4.5 per 100 PYAR in the control arm. Furthermore, in 
2009, feasibility cohorts (40) conducted at trial sites before trial roll out showed annual HIV 
incidence of 6.2 per 100 PYAR. Investigators used HIV incidence of 4 per 100 PYAR to estimate 
the trial sample size citing the reason that women that correctly identified themselves at high risk 
of HIV infection may have been the first to come forward to participate in the feasibility cohorts.  
At the end of trial follow up, they observed HIV incidence of 4.3 per 100 PYAR in the control arm 
(44).  
These clear differences in HIV incidence between trial control arm and source population 
observational data could mean that observational data should be used with caution while planning 
efficacy trials especially in populations without previous efficacy trial experience such as members 
of fishing communities on shores of Lake Victoria and Female sex workers in Kampala, Uganda. 
An astute clinical/statistical team should consider adjusting for these differences when estimating 
the required trial sample size.  
1.3.2 Need for reliable contraceptives use in HIV vaccine efficacy trials 
HIV vaccine efficacy trials recruit both men and women. These trials take months or years from 
recruitment to completion of follow up, therefore women could become pregnant. Women who 
become pregnant have to be withdrawn from vaccination to avoid exposing the foetus to a product 
whose effects are not known. Lately, there is a call to find vaccine candidates that allow inclusion 
of pregnant women in trials (45-47). Before this happens, more withdrawals of pregnant women 
from trials than that anticipated could significantly lower the trial sample size and negatively effect 
the trial statistical power. If women withdrawn from the trial follow up due to pregnancy are also 
those more likely to sero convert that would lower the estimated HIV incidence. Therefore, HIV 
vaccine efficacy trials need to be conducted in women who are not pregnant and willing to delay 
pregnancy. These trials need participants to be sexually active and potentially exposed to HIV, so 
it is important to prevent pregnancies through use of reliable, long-acting, reversible contraceptive 
methods. Cultural and logistical challenges in addition to the need to use and adhere to long-term 
contraceptive use among women may make it difficult to recruit them into such HIV vaccine 
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efficacy trials (48). The need to use reliable contraceptives excludes from trials women who do 
not want to use contraceptives and those wanting to get pregnant, creating a significant potential 
for selection bias.  
1.3.2.1 Reliable contraceptives use, pregnancy incidence in previous HIV prevention trials  
The baseline reliable contraceptives use reported in the previous efficacy trials of non HIV vaccine 
but other HIV preventive products in Africa has ranged 8.3% to 39% (38, 39, 49, 50) with minimal, 
33% - 65% increase in their use reported during follow up (51). The incidence of pregnancy from 
these and other efficacy trials in Africa has ranged from 1 to 27 pregnancies per 100 women-years 
(52). These trials mainly recruited Women in HIV sero-discordant couple relationship (49-51) or 
in the general population (38, 39, 42).   
1.3.2.2 Reliable contraceptives, pregnancy incidence in previous HIV vaccine efficacy trials   
Of the concluded HIV vaccine efficacy trials (53, 54), only one reported data on reliable 
contraceptives use and incidence of pregnancy (55). In this trial, 36% of the women reported use 
of reliable contraceptives at baseline and no data on uptake during follow up is provided. The 
annual incidence of pregnancy was 9.6 per 100 women-years of follow up. These HIV vaccine 
efficacy trials recruited participant from the general population in South Africa (53) and Thailand 
(54).  
1.3.2.3 Reliable contraceptives use and pregnancy incidence in FF and FSW 
To date, no HIV vaccine or other efficacy trials have completed follow up in FSW in Kampala and 
FF on the shoreline of Lake Victoria in Masaka or elsewhere. Therefore, there is limited or no 
baseline data on uptake and use of reliable contraceptives to be used in planning HIV vaccine 
efficacy trials targeting women and their spouses in these key populations. Such data will have to 
come from observational or pilot studies. Observational studies conducted in these key populations 
in Uganda (56, 57) and elsewhere (58) have shown low contraceptives use 11%-60%. In Uganda, 
the only previous observational study (57) to report data on reliable contraceptives use in the FF 
showed that 35.2% of the women use reliable contraceptive methods. This is similar to 35% 
reported in the general population (59) in Uganda but lower than 59.6% shown in the FSW 
population in Kampala (56). The high reliable contraceptives use in the FSW population could be 
linked to the occupational demands of sex work. All the women, 100% in the FSW population 
depend on sex work for livelihood and unprotected sex has been associated with higher pay (36) 
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but higher risk of unwanted pregnancy. The need to stay free from pregnancy to satisfy male 
clients’ demand for sex could be the motivator for the higher reliable contraceptives use. 
One systematic review of observational cohorts of female sex workers in Low and Middle-income 
countries in Africa showed pregnancy incidence of 7 to 60 per 100 women years (60). This high 
incidence of pregnancy if replicated in future HIV vaccine efficacy trials anticipated in FSW or 
FF in Uganda, could have a far-reaching effect on the trial statistical power. It is important that 
women participating in HIV vaccine efficacy trials in these key populations use reliable 
contraceptives. Therefore, investigators will need baseline data on reliable contraceptives use in a 
trial specific context in these populations.  
1.3.2.4 Contraceptives use data for planning efficacy trials (current practices) 
Use of reliable contraceptives (non-barrier methods likely to reduce the risk of pregnancy) has 
become a key inclusion criterion in HIV prevention trials (61). In populations where no baseline 
data on reliable contraceptives use in a trial specific context is available, there is a practice of 
putting prospective trial participants on reliable contraceptive methods for at least three months 
before screening and enrolment (62). This increases the cost of conducting trials and delays rollout, 
but avoids costly dropout from trials due to non-compliance. Therefore, studies aimed at 
establishing reliable contraceptives use under HIV-vaccine efficacy trial conditions would provide 
baseline data for planning actual HIV vaccine efficacy trials in the FF and FSW populations where 
little or no information is available. 
1.3.3 Study dropout rates in FSW and FF Key populations in Uganda   
Another essential component of efficacy trial is good participant retention in follow up. One of the 
primary outcomes of any longitudinal study is the completion of the scheduled study follow up 
visits by the study participants (63). Studies have suggested that participants who do not complete 
study follow up may be more likely to experience the outcome of interest, resulting in an 
underestimate of the incidence of the primary study outcome (63, 64). Studies conducted in the FF 
and FSW in Uganda have estimated participant study dropout ranging 25-30% (28, 33, 34). In 
these feasibility studies, we see big dropout in the first six months, or at the first study visit, then 
stabilization over time (33, 34). Again, this information comes from observational cohorts and 
there is evidence suggesting that observational cohorts are usually different from efficacy trials. 
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Dropout rate in HIV vaccine efficacy trials planned in the FSW and FF in Uganda could pose a 
challenge if it is beyond that expected. However, it is expected that trials have better retention 
compared to observational cohorts. Therefore, estimation of actual dropout in the context of HIV 
vaccine efficacy trials in these key populations could provide robust data needed to guide the 
design of HIV vaccine efficacy trials in these populations.  
1.3.4 HIV behavioural risk components in previous trials  
Lastly but not least, lower than expected HIV incidence and hence loss of trial statistical power 
may be due to “better than usual” conditions (behavioural change messages and comprehensive 
HIV prevention package). The HIV risk reduction measures targeting behaviour change in trials 
could produce lower than anticipated HIV incidence and affect the trial statistical power.  In the 
concluded HIV prevention trials (38, 39, 42), it has been shown that participants who join the trials 
tend to incline to lower HIV risk behaviour following vigorous trial risk-reduction measures. 
Ethics require that participants joining HIV vaccine efficacy trials be provided with the standard 
of care that encompass all biomedical and behavioral interventions known to prevent against HIV 
acquisition. Some of the concluded HIV prevention trials (38, 39) have shown that HIV risk 
reduction measures such as counselling on HIV risk behaviours increased the proportion of 
participants taking up HIV prevention measures that included condoms use with a new sexual 
partner, reduction in the number of sexual partners, number of sex acts and alcohol use. The 
response to HIV risk reduction measures in these trials, were thought to have led to the diminished 
HIV incidence beyond that predicted at trial design even in absence of an effective new biomedical 
product.  
1.3.4.1 HIV behavioural risk components in FF and FSW in Uganda  
Observational studies in the FF (27, 33, 34) in Masaka and FSW (65, 66) in Kampala Uganda have 
indicated very high levels of alcohol use, multiple sexual partners, non-condom use with these or 
a new sexual partner and high prevalence of other genital infections. Efficacy trials’ controlled 
environment encompassing among others, frequent clinic visits for interventions such as HIV 
counselling and testing, HIV risk-reduction counselling, promotion and provision of condoms and 
treatment of other genital infections could lead to diminished HIV incidence in HIV vaccine 
efficacy trials planned in FF and FSW in Uganda even without an effective vaccine. Again, 
determining the decrease in HIV risk behaviours in these key populations in the context of HIV 
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vaccine efficacy trials could provide useful information for planning future trials in these 
populations.  
1.3.5 Simulated HIV Vaccine Efficacy Trials (SiVET) 
Simulation trials could help bridge the gap when extrapolating observational data to planning HIV 
vaccine efficacy trials in key population in Uganda.  SiVET is a process of mimicking an actual 
vaccine efficacy trial using a commercially licensed vaccine as a proxy vaccine to provide insight 
and help guide the design of an actual efficacy trial, particularly where no previous trial specific 
information is available. This concept has been used elsewhere to see if women can participate in 
HIV vaccine trials (67). Participants in this simulation trial received attenuated commercially 
licensed MMR vaccine (measles, mumps, and rubella), Tdap-IPV vaccine (Tetanus toxoid, 
reduced diphtheria toxoid and acellular pertussis) as a proxy for an experimental HIV vaccine.  
1.3.5.1 SiVET in FF and FSW key populations in Uganda   
In anticipation of HIV vaccine efficacy trials in the FF and FSW key populations in Uganda, the 
MRC/UVRI and LSHTM Uganda research unit in partnership with IAVI conducted two HIV 
simulated vaccine Efficacy Trials (SiVETs) between 2012 and 2017. The primary purpose of 
SiVETs was to determine if members of these key populations could accept and complete 
vaccination schedule in a trial specific context; additionally, they served to train trial staff.  SiVETs 
were nested in long-term observational cohorts of FF and FSW. The aims of the observational 
cohorts were to determine HIV incidence and also create an enrolment pool of participants for 
future HIV prevention trials. Full details of the observational cohorts and SiVETs have been 
previously described (26, 29, 68-70). SiVET used a commercially licensed Hepatitis B vaccine in 
a study that followed the same procedures as a trial of an experimental HIV vaccine.  
Because no HIV prevention trials have completed follow up in the FF or FSW to provide baseline 
data needed to plan HIV vaccine efficacy trials in these key populations, many elements for trial 
design such as; accurate HIV incidence, trial dropout and use of reliable contraceptives by women 
participants remain unknown. This PhD aimed at using the data collected in SiVETs as well as the 
source observational cohorts to provide this important information. Answering the PhD objectives 
has huge potential to inform investigators planning HIV vaccine and other efficacy trials in these 
and similar key populations.  
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Chapter 2: Thesis aim, objectives, structure, my contributions to studies 
included in the thesis and an outline of relevant publications 
2.1 Introduction 
This chapter presents the thesis aim, objectives, structure and my contribution to the conception 
and conduct of studies whose data was used in this thesis. 
2.2 Thesis aim 
To plan HIV vaccine efficacy trial, most data on targeted trial outcomes or other trial elements 
come from previous trials of the same or similar population. Where such data is not available, 
historical cohorts or other observational data may be used. However, observational data may not 
emulate the trial data because of the trial selection procedure and/or trial controlled environment. 
Therefore, the primary aim of this thesis was to investigate how the targeted outcome elements in 
HIV vaccine efficacy trials might differ from those in the source population observational cohorts 
within which they were nested. 
2.3 Thesis objectives 
1. To investigate how HIV incidence estimated from observational cohorts might differ from 
that in the HIV vaccine efficacy trials in the same population. 
 
2. To determine uptake and use of reliable contraceptives by women participating in HIV 
vaccine efficacy trials.  
 
3. To estimate and compare observational cohorts’ participant dropout rate to that in HIV 
vaccine efficacy trial in the same population. 
 
4. To compare HIV risk behaviours between trials and observational cohorts in the same 
population. 
The four thesis objectives were answered through analysis of data collected in two longitudinal 
observational cohorts (OBC) and two simulated HIV vaccine efficacy trials nested within the 
OBCs in the Fisher-folk (FF) in Masaka district and Female sex workers (FSW) in Kampala city, 
Uganda.  Prior to the SiVET, the total number of participants enrolled in these observational 




2.4 Thesis structure 
The thesis consists of eight chapters and is written following the LSHTM ‘research paper’ style 
format, with four research papers. Each research paper was prepared as a standalone manuscript. 
Therefore, in some instances, there is minimal repetition of some information in the background, 
study setting, and inclusion-exclusion criteria among the different research papers. 
 
 Chapter One: This thesis background chapter reviews the literature on HIV efficacy trials 
with emphasis on HIV vaccines, the likely pitfalls in extrapolation of observational data to 
planning efficacy trials, describes the current practices used to plan efficacy trials in 
populations without previous trial experiences, and gives summary justification.  
 Chapter Two: Summarises the thesis primary aim, objectives, structure, and my role in 
the conception and acquisition of the data in the cohorts used in this thesis. 
 Chapter Three: This is comprised of the thesis methods, definitions and classifications of  
the terms used throughout the thesis and description the methods used to answer thesis 
objectives 1, 2, 3 and 4 
 Chapter Four: Presents thesis objective one “How HIV incidence estimated from 
observational cohorts might differ from that in the HIV vaccine efficacy trials in the same 
population” 
 Chapter Five: Presents thesis objective two “Determine uptake and use of reliable 
contraceptives by women participating in HIV vaccine efficacy trials” 
 Chapter Six: Presents thesis objective three “Comparing participant dropout rate in the 
observational cohorts and HIV vaccine efficacy trials in the same population” 
 Chapter Seven: Presents thesis objective four “Comparing HIV risk behaviours between 
trials and observational cohorts within which they were nested” 
 Chapter Eight: The discussions chapter summarises the PhD findings in relation to the 
existing literature, implications of the findings, strengths, limitations and conclusions.  
 Appendix section captures other information relevant to this thesis. These include but not 
limited to ethical approval, training certificates and conference presentations.   
Research papers one to four, where applicable, have been written following guidelines from 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (71). 
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2.5 Candidate’s contribution 
I joined MRC/UVRI and LSHTM Uganda Research Unit in 2007, since that time I have had many 
career growth opportunities, growing through ranks from a Statistical Research Associate to 
Acting Head of Statistics Department. In the period between 2007 and 2020, I carried out data 
management for 17 studies (11-Observational and 6-Randomised Controlled Trials (RCTs)). In 
the same period, I conducted statistical analyses for 15 studies (8 –Observational and 7-RCTs). I 
have been a co-investigator on four studies (3-Observational and one-RCT). Additionally, I 
participated in fieldwork data collection in two observational studies. During the same period, I 
led a team in the Statistics Department at MRC/UVRI and LSHTM Uganda research unit, directly 
supervising eight Statisticians, nine data managers, two database programmers, 25 data 
management assistants and 4 performing other roles.  
2.6 My role in the cohorts whose data were used to answer the PhD objectives  




Led the data management  
team 
Developed the data Standard Operating 
Procedures (SOPs), trained the data management 
team to ensure that the data collected conforms to 
the protocol guidelines and Good Clinical 
Practice. 
Cohort Statistician  Developed the data collection tools, data 
management and data analysis plans, analysed 
the data and co-authored the primary manuscript. 




Co-investigator  Participated in the protocol development through 
discussions of the scope, analysed data from 
previous cohorts to inform the design and conduct 
of this cohort and estimated the sample size.  
Led the cohort’s data 
management team  
Developed the data Standard Operating 
Procedures, data collection tools, guided the 
database development, periodically checked the 
data for errors (inconsistencies, missing forms 
and fields) as part of periodic data monitoring.  
Cohort Statistician  Developed the data analysis plan and analysed the 
data for periodic cohort reports and the final 






Led the Statistics and Data 
Management Teams   
Key roles were limited to supervising the Statistics 
and Data Management team directly involved in 




SiVETs  Co-Investigator  Conception of the simulated HIV vaccine trial 
(SiVET) concept. Participated in the protocol 
development through decisions of the scope, 
design, conduct and sample size estimation. 
Participated in the development of the Study 
Operations Manual (SOM), and Standard 
Operating Procedures.  
SiVETs Statistician and 
Head of Data Management 
team 
Developed the data collection tools, data 
management and analysis plans, analysed the 
data and co-authored the primary manuscripts 
from the SiVETs (Second co-author on SiVET1 
(FF) and SiVET2 (FSW) papers).   
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2.10 Conferences and workshop presentations of cohort data during  my PhD studies   
No Date Presentation title  Mode  Type & location  
1 Oct 21-25,2018 Uptake and use of reliable 
contraceptives and correlates of 
use among women participating in 
HIV efficacy trials preparatory 




HIVR4P, 2018 Madrid 
Spain. 
2 Mar 04-07,2019 Simulated Vaccine Efficacy Trials 
to estimate HIV incidence in key 
populations in Uganda.  
Poster 
(1088) 
CROI, 2019 Seattle 
Washington United 
States of America. 
3 Jun 03,2019 Use of reliable contraceptives by 
women participating in HIV 
Simulated Vaccine Efficacy Trials 
in key populations in Uganda 
Oral 
seminar  
The Population Studies 
Group (PSG), LSHTM, 
United Kingdom.  
4 Oct 22,2019 Using observational cohort data 
from Key populations to plan HIV 
intervention studies  
Oral 
seminar  
MRC/UVRI & LSHTM 




5 Nov 29,2019 Using observational cohort data 
from Key populations to plan HIV 
intervention studies  
Oral 
seminar 
MRC/UVRI & LSHTM 
Uganda Research Unit, 
senior scientific 




2.11  Other relevant transferrable skills and other training in the course of my PhD studies  
No Date Training , location Training organizer  
1 Apr 26-May 19,2017 Advanced statistical methods in 
Epidemiology (ASME), LSHTM  
London School of Hygiene and 
Tropical Medicine  
2 Nov 13-17,2017 Scientific Manuscript Writing 
Workshop, Johannesburg  
South Africa National Blood 
Services Johannesburg 
3 Nov 22-23,2017 Study designs, MRC/UVRI and 
LSHTM Uganda Research Unit 
MRC/UVRI and LSHTM 
Uganda Research Unit 
4 Jul 09-27,2018 Scientific manuscript writing 
mentorship, University of 
California   San Francisco  
University of California San 
Francisco Centre for Global 
Health  
5 Aug 20-31,2018 Uganda Advanced Statistical 
Methods course (UASME), 
MRC/UVRI and LSHTM  
MRC/UVRI and LSHTM 
Uganda Research Unit  
6 Feb 25-Mar 01,2019 Scientific Manuscript writing 
workshop, University of Nairobi 
Kenya 
International AIDS Vaccine 
Initiative (IAVI) 
7 Apr 03,2019 Assessing data quality and 
disclosure risk in numeric data 
workshop, LSHTM 
London School of Hygiene and 
Tropical Medicine 
8 Apr 25-May 17,2019 Advanced Statistical Modelling 
(ASM), LSHTM 
London School of Hygiene and 
Tropical Medicine 
9 May 22,2019 Preparing to submit your thesis, 
LSHTM 
London School of Hygiene and 
Tropical Medicine 
10 Jul 08-26,2019 Scientific manuscript writing 
mentorship University of 
California   San Francisco 
University of California San 





Chapter 3: Methodology 
3.1 Introduction 
This chapter describes in detail the longitudinal observational cohorts (OBCs) and the HIV 
Simulated Vaccine Efficacy Trials (SiVETs) cohorts used to answer the PhD objectives. It also 
provides the study settings, detailed cohort descriptions, data layout, estimation of the minimum 
sample size for each objective, statistical methods for each thesis objective, ethical considerations, 
defines and classifies the terms used in the thesis. 
3.2 Definitions and classifications  
Fisher-folk (FF): This term refers to not only fishermen but to all people living on the lakeshore 
who directly or indirectly derive their livelihoods from the fishing industry. These include fish 
traders, fish processors, boat builders, members of families of fishermen, restaurant and bar 
workers, sex workers and others engaged in small-scale businesses (33). 
Fishing community: A group of persons living in a village or trading Centre that is adjacent to 
lake landing site where the main economic activities and livelihood are derived directly or 
indirectly from fishing activities (72). 
Sex work: The provision of sexual services for money or other goods (73). 
Female sex worker (FSW): A woman receiving money, goods or other favours in exchange for 
sexual services with a non-legal spouse and who consciously defines that activity as income 
generating even if she does not consider sex work as her occupation (73). 
Clients: Men who usually pay with cash or other resources for sexual services either explicitly or 
within an agreed package that includes other services such as entertainment or domestic service 
(73).  
Source population: This refers to Fisher-folk or female sex worker populations.  
Observational cohort (OBC): Longitudinal prospective follow up of participants in a study of FF 
or FSW to determine HIV incidence among other evaluations.  
Simulated HIV Vaccine Efficacy Trial (SiVET): A process of mimicking an actual HIV vaccine 
efficacy trial using a commercially licensed vaccine (Hepatitis B vaccine in this case) as a proxy 
vaccine (29).  
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Pre SiVET cohorts: Longitudinal observational cohorts conducted in the period prior to the 
initiation of the SiVET cohort in a given source population. More specifically , Sept 2009- June 
2012 in the FF population and Apr 2008- Apr 2014 in FSW population.  
Non-SiVET cohorts: This refers to participants that screened failed or were not screened into 
SiVET because of SiVET recruitment accrual but fulfilled the inclusion exclusion criteria for 
continued follow up in the given source population observational cohort.  
 SiVET concurrent period: Refers to the period of conduct of non-SiVET and SiVET cohorts. 
Non-SiVET cohort in the SiVET concurrent period began on the date the SiVET cohort began 
enrollment, and ended on the date of the last SiVET participant clinic visit in a given source 
population. 
Post-SiVET cohorts: All prospective observational cohort data for 12 months after the final 
SiVET participant study visit in a given source population. 
Reliable contraceptives: Non-barrier contraceptives methods likely to reduce the risk of 
pregnancy (51). These included injectable Depot medroxyprogesterone acetate (DMPA), pills, 
Norplant-implant and intrauterine contraceptive device (IUD). 
3.3 Study setting 
The data used to answer the PhD objectives one to four were obtained from longitudinal 
observational cohorts and SiVETs nested within these observational cohorts in two key-
populations in Uganda, (i) the Fishing communities on the shore of Lake Victoria in Entebbe and 
Masaka Uganda (Feb 2009- Apr 2015) and ii) female sex workers in Kampala Uganda (Apr 2008-
Apr 2018).  
3.3.1 Fishing communities  
3.3.1.1 Location  
These are located on the shoreline of Lake Victoria in Entebbe and Masaka district, respectively, 
about 40km and 100 km from Kampala city, the capital of Uganda (Figure 1). The fishing 
communities are on average 10km from the Trans-African high way (high way stretching from 




Figure 1: Location of the fishing communities on the shoreline of Lake Victoria in Uganda 
3.3.1.2 Structure  
A typical fishing community consists of wattle-and-mud or corrugated metal iron sheet wall-and-
iron sheet roof houses with one or two rooms (figure 2 and 4). The communities are concentrated 





Figure 2: Typical fishing community settlement in Masaka district, Uganda 2012 
 
Figure 3: Typical fish landing site on the shore of Lake Victoria, Uganda 2012 
3.3.1.3 Economic activities in the fishing communities  
Although the main economic activity is fishing, other activities support the fishing occupation. 
These include but are not limited to small-scale fish processing (figure 4), work in 
restaurants/bars/hair salons to serve a wide range of individuals, small-scale businesses, carpentry 
shops making wooden boats, and film shows among others. 
Source: Abaasa A 




Figure 4: Silver fish processing (drying on the sand) on the shoreline of Lake Victoria, 
Uganda 2012  
Because of the wide range of economic activities, studies in these communities recruit participants 
from all the occupations but the term fisher-folk (section 3.2) is used to refer to all participants in 
the studies and in this thesis.  
3.3.1.4 Local leadership and health care in fishing communities  
These fishing communities have administrative structures including the local government councils 
and the beach management units that take care of all administrative needs on behalf of the central 
government (74).  Individuals in these communities live in clusters of isolated locations and this 
makes it difficult for them to access basic healthcare services. They lack access to safe water, 
latrines etc., making them vulnerable to illness. They have to move further afield to seek for health 
care needs in established government of Uganda health centres, located between 10km to 40km 
from the fish landing sites or to more specialized regional referral hospitals in Masaka and Entebbe 
(figure 5).   





Figure 5: Masaka and Entebbe, Uganda government regional referral 
hospitals 2012 and 2018 
3.3.1.5 Estimated population of and HIV epidemiology in fishing communities in Uganda  
3.3.1.5.1 Population size  
The fishing communities on the Lake Victoria basin in Uganda are estimated to have over 400 fish 
landing sites (72), each fishing community having about 250 households with average household 
size of four individuals. This translates to about 400,000 individuals in these communities.  A more 
recent study using satellite images identified 509 fishing communities in Uganda and estimated 
the total population size of about 320,000 individuals (75).  
3.3.1.5.2 HIV and risk behaviour epidemiology  
The adult HIV prevalence is estimated to be about 25% (31, 76) and annual HIV incidence of 5 
per 100 person years at risk (27). These vary with population subgroups (27). The FF population 
is characterised by very high HIV risk behaviours such as multiple sexual partnership, with 87% 
reporting having more than one sexual partner, and only a quarter reporting condom use with these 
partners (76). The prevalence of other sexually transmitted diseases and infections is equally high; 
syphilis (3.6%), general STIs (19.0%), reported genital discharge (19.5%) and sores (29.0%) (76).  
More than half of the adult population regularly consume alcohol (76)  and only 35% of the women 











3.3.2 Female sex workers  
3.3.2.1 Location  
Female sex workers defined in section 3.2 operate within Kampala city’s hangout places including 
bars, restaurants and selected city streets. These places are within a radius of 5KM from the 
MRC/UVRI and LSHTM Uganda Research clinic at Mengo hill, which is about 2 KM from the 
city centre (figure 1).   
3.3.2.2 Structure  
Women in the sex work occupation meet their clients on the streets and/or nightclubs (figure 6) 
and retreat to lodges within the city for sexual activity. The lodges are hired for as low as $3 to $ 
10 depending on the duration of stay and location.  
 
Figure 6: Setup of nightclubs and streets in Kampala city where sex workers meet clients   
 
3.3.2.3 Health care access  
Female sex work in Uganda is illegal therefore; women operate undercover for fear of being 
identified and rested by the police. This makes provision of health care to this particular group 
difficult. However, of late these women and their well-wishers are demanding for rights to operate 







Figure 7: Female sex workers and well-wishers demanding for rights to operate freely in 
Uganda  
 
Studies in this population recruit women operating from HIV hot spots  in Kampala city including; 
bars, night clubs, local beer breweries, eating places, lodges and guesthouses known to provide 
rooms for sex work, or selected street spots often frequented by sex workers in search of clients 
(65). 
3.3.2.4 Estimated population of and HIV epidemiology in FSW in Uganda  
3.3.2.4.1 Population size  
The FSW population in Uganda is estimated at about 192,000 and about 40% operating from 
Kampala city, the capital of Uganda (77). Sex work in Uganda is illegal and this creates challenges 
of identifying individuals engaged in this activity, making provision of health care services 
difficult.  
3.3.2.4.2 HIV and risk behaviour epidemiology  
The HIV prevalence in this population is estimated at between 33% and 37% (65) and annual HIV 
incidence of about 3 per 100 PYAR (25, 29). The prevalence of other sexually transmitted diseases 
and infections is equally high; N. gonorrhoea 13%, C. trachomatis 9%, T. vaginalis 17% and 
syphilis 21%, bacterial vaginosis 56% and candida infection 11% (65).  
Similarly, this population is characterised by high multiple sexual partnerships, with over 80% 
reporting having sex with more than one partner in the last month. The reported condom use with 
these partners is very low at 40% and the use of contraceptives other than condoms is equally low 







3.4 Description of FF, FSW observational, and SiVET cohorts used in this PhD thesis  
3.4.1 FF observational cohort pre SiVET 
Two successive OBCs (Feb 2009 - Dec 2011, and Jan 2012 - Apr 2015) were established in this 
population. The first OBC recruited 1000 participants from five fishing communities, three in 
Entebbe sub district and two in Masaka district, Uganda.  The five fishing communities were 
selected using pre-defined criteria; located within 50km from MRC/UVRI and LSHTM research 
clinic in  Entebbe (50Km, South of Kampala) or Masaka town (100km, West of Kampala),  ≥ 1000 
adults (≥18 years) and gazetted by Uganda Ministry of Fisheries. The primary aim of this cohort 
was to investigate the possibility of enrolling and retaining FF in follow up in an OBC but also 
determine HIV incidence. 
To establish this cohort, trained field workers mapped households in the five communities, carried 
out a census, and assigned identification numbers to all residents and regular visitors. They sought 
written consent and offered screening for HIV to those aged 18-49 years at the study clinics 
established in each of the five fishing communities. They referred those found to be HIV positive 
to a local HIV services provider for HIV treatment and care. The rest were enrolled into an 
observational cohort with six monthly follow up clinic visits (for HIV testing and behavioural risk 
assessment) for 18 months, if they were HIV negative and at high risk for HIV infection. High risk 
was defined as self-report of any of the following in the previous 3 months: unprotected sex with 
≥one or new sexual partners, history of sexually transmitted infections (STIs), use of illicit drugs 
and/or alcohol, and being away from home for ≥2 nights per week. Data were collected on 
demographic and behavioural risk variables using a structured questionnaire and a blood sample 
taken to determine HIV status at baseline and at each of the follow up visits. The census and cohort 
details are previously described (27, 33, 76). 
In this first FF cohort, participant recruitment and follow up happened at clinics established in each 
of the participating fishing communities but future HIV vaccine efficacy trials may not take place 
at the clinics established in the fishing communities because of lack of adequate infrastructure such 
as laboratory, vaccine pharmacy and office space to conduct large phase trials. Therefore, the first 
FF cohort data was used to inform the design of the second FF cohort (similar aims as the first one 
but also to create a pool of participants to enroll in future HIV prevention trials) and was planned 
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to maintain at least 400 volunteers in follow up at any one time. Unlike the first FF cohort, 
participants in the second FF cohort had to travel (for all their study visits) to the MRC/UVRI and 
LSHTM research clinic (with all HIV vaccine efficacy trial infrastructure) located in Masaka town, 
about 50km from the fishing communities. Similar procedures as the first FF cohort were followed 
to establish the second FF cohort but follow up for HIV counselling and testing happened every 
three months. At each clinic visit completed, participants received approximately $1.4 as 
reimbursement for the cost of transport and compensation for time.  Similarly, the cohort details 
have been previously described (26, 29, 34).  
3.4.2 FSW observational cohort  
The FSW cohort Apr 2008 - Apr 2018 was established at MRC/UVRI and LSHTM Uganda 
research Unit’s Mengo field station in Kampala city. The primary objective of establishing this 
cohort was similar to that of the two FF cohorts, section 3.4.1 above. To establish the FSW cohort, 
trained fieldworkers identified and mapped hotspots initially in the two (Makindye and Rubaga) 
of the five divisions of Kampala city until 2010 when it was expanded to include all the five 
divisions (Makindye, Rubaga, Kawempe, Nakawa and Kampala central). The hotspots were 
defined as clusters of bars, nightclubs, local beer breweries, eating places, lodges and guesthouses 
known to provide rooms for sex work, or selected street spots often frequented by sex workers in 
search for sexual clients. The fieldworkers’ mobilised women engaged directly in female sex work 
or employed around the entertainment facilities and invited them to the cohort clinic at 
MRC/UVRI and LSHTM office. At the clinic, information about the cohort objective was provided 
to the women by the study staff that included physicians, nurses and counsellors. Those willing 
(providing written informed consent) to join the cohort were screened for eligibility. Those eligible 
(aged≥18years, HIV negative, engaged in female sex work) were given an appointment to return 
within one week for their enrolment visit. Those found to be HIV positive were referred to a local 
ART treatment and care provider. At enrolment visit, data were collected on socio demographic 
and HIV behavioural risk using interviewer administered questionnaires. Participants were 
scheduled to return every 3 months for follow up visits. At each of the follow up visits, repeat HIV 
testing was done and behavioural risk assessment at annual visits. At each clinic visit completed, 
participants received approximately $1.2 as reimbursement for the cost of transport and 
compensation for time. Similarly, the cohort details have been previously described (25, 29, 65).  
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3.5 HIV risk reduction measures in the observational cohorts 
Participants in observational cohorts received HIV counselling and testing every three months, 
counselling on having concurrent multiple sexual partners or causal sexual partners and were 
provided with condom on request. Participants in these cohorts only received presumptive 
treatment for sexually transmitted infections if a study physician suspected an infection.  
3.6 HIV Simulated Vaccine Efficacy Trials (SiVETs)  
SiVET1 and SiVET2 cohorts were nested within the observational cohorts in FF and FSW 
respectively. SiVETs were carried out to determine the feasibility of conducting HIV vaccine 
efficacy trials among the two HIV high risk key populations in Uganda, but using a commercially 
licensed hepatitis B vaccine (ENGERIX-BTM GlaxoSmithKline Biologicals Rixensart, Belgium) 
as a proxy vaccine.  
3.6.1 SiVET population  
Participants were recruited into SiVETs in FF and FSW if they fulfilled the inclusion exclusion 
criteria in table 1 below.  
Table 1: SiVET and non-SiVET cohorts’ inclusion exclusion criteria in the SiVET 
concurrent period  
Time SiVET cohorts non-SiVET cohorts  
 Inclusion 
 At least 3 and no more than 18 months of 
follow up in the parent source population 
observational cohort 
 HIV-1 negative and willing to undergo 
HIV testing 
 Aged ≥18 years and ≤49 years  
 Able and willing to provide written 
informed consent 
 Able and willing to provide adequate 
locator information 
 Able and willing to return for follow-up 
clinic visits 
 Intending to reside in study area for at 
least one year  
 Willing to undergo pregnancy testing  
 Not breastfeeding and no intent for 
pregnancy in the next one year 
Inclusion  
 At least 3 months and no more 
than 18 months of follow up in the 
parent observational cohort 
 Aged ≥18 years and ≤49 years  
 HIV negative  





















 Willing to use effective contraception 
during the study and at least 3 months 
after the last vaccination 
Exclusion 
 History of severe allergic reaction to any 
substance  
 An acute or chronic illness 
 Contraindication for Hepatitis B vaccine  
 Participation in another clinical trial 
 Hepatitis B positive (only SiVET2) 
Exclusion  
 HIV positive  
3.6.2 Administration of Hepatitis B vaccine  
In addition to the procedures (HIV testing and risk assessment) in the parent observational cohorts, 
SiVET participants were administered 1ml of a commercially licensed Hepatitis B vaccine 
(ENGERIX-B GlaxoSmithKline Biologicals Rixensart, Belgium) following the standard 
schedule of 0, 1 and 6 months, akin to what might happen in an actual HIV vaccine efficacy trial. 
In line with HIV vaccine efficacy trial, participants had a reactogenicity assessment at least 30 
minutes after each vaccination and attended a post vaccination visit three days later. Other trial 
visits were scheduled at months 3,5, 8, 9 and 12 and trial visits had scheduled clinic visit windows 
as follows: vaccination visits (±3 days), 3-day post vaccination visits (±1 day) and all other visits 
(±7 days).  
3.6.3 HIV risk reduction measures  
3.6.3.1 Counselling interventions  
Participants received HIV counselling and testing every 3 months and counselling on HIV risk 
behaviours including; alcohol consumption, alcohol use before sex, multiple or causal sexual 
partnerships among others, every six months.  
3.6.3.2 Other interventions  
A trial counsellor promoted and provided condoms to participants estimated (depending on 
frequency of sex defined by participants) to last them the period before returning to the clinic for 
the next follow up visit. Participants were also encouraged to return to the clinic for more condoms 
in case they ran out before the next scheduled visit. A trial physician carried out physical 
examinations diagnosed sexually transmitted infections and other genital infections at the visits 
happening every six months. Those found infected with STIs were treated before leaving the trial 
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clinic or asked to return for their results and receipt of treatment. All participants were encouraged 
to return to the clinic any time for checkup whenever they did not feel well.  
3.6.4 Reliable contraceptives 
To prevent pregnancy, a trial nurse promoted and provided reliable contraceptives (injectable 
Depot Medroxyprogesterone Acetate (DMPA), implant, pills, and intrauterine device (IUD)) 
according to women’s choice to women who were not using a reliable method at enrolment. Those 
already using a reliable method were encouraged to continue with their method. Contraceptive use 
data were recorded at baseline and at each of the follow-up clinic visits. 
3.6.5 Participant clinic follow up schedule and procedures  




Table 2: Procedures conducted at each trial scheduled clinic visit  
Procedures 







M 3 M6* 
M6+ 
3days 
M 9 M 12 
Hepatitis B vaccination X  X   X    
HIV risk assessment 
questionnaire 
X     X   X 
Medical history, including 
STI  
X         
Physical exam, vital signs, 
height, weight, genital exam 
X         
Directed medical history, 
including STI 
 X X X X X X X X 
Directed physical exam, 
genital exam 
 X X X X X X X X 
HIV counselling and testing  X  X  X X  X X 
Promotion and provision of 
condoms  
X  X  X X  X X 
Contraception promotion 
and provision   
X  X  X X    
Concomitant medication 
assessment 
X X X X X X X X X 
Local and systemic 
reactogenicity  
X X X X  X X   
Adverse events  X X X X X X X X X 
Serious adverse events  X X X X X X X X X 
Urine pregnancy test 
(women) 
X  X  X X  X X 
Syphilis serology X        X 
*Vaccination visits, M-month 
3.6.6 SIVET sample size determination  
SiVETs were powered on assessment of retention within one year among participants enrolled 
from observational cohorts in the fishing communities in Masaka and female sex work in Kampala. 
The assumption was a retention of 80% or more at one-year would be sufficient to inform future 
HIV vaccine efficacy trials in these populations.  SiVET concept would improve retention from 
72% (average retention from previous observational cohorts in these populations) to at least 80% 
at 5% level of significance and 80% power. Under these assumptions, a sample size of 233 
participants in each SiVET was required to allow for assessment of retention. This sample was 
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increased by 20% (assumed average loss to follow up in these populations) giving a minimum of 
total sample size of 280 i.e. 560 for both SiVETs (one in each of FF and FSW populations). 
3.7 Stratification of cohorts data used in this thesis  
To create clarity in the comparisons in this thesis and throughout the publications included, the 
designs and meaning of each of Pre SiVET, SiVET, non-SiVET, SiVET concurrent and post-
SiVET cohorts are provided in this section. Figure 9 below, shows more details of the same.   
3.7.1 Pre SiVET cohort data 
Though in some cases this has been stratified by the source population (FF or FSW), generally, 
pre SiVET cohorts data throughout this thesis will refer to observational cohorts data before 
conduct of SiVET in that source population. Specifically, data from participants enrolled in the 
observational cohorts between Feb 2009 and Jun 2012 in the FF and Apr 2008-Jul 2014 in the 
FSW, figure 9.  
3.7.2 SiVET cohorts data 
Similarly this may be stratified by the source population but generally SiVET cohort data 
throughout this thesis will refer to data from participants enrolled into SiVETs nested within the 
FF observational cohort (Jul 2012-Apr 2014) and within the FSW observational cohort (Apr 2014-
Apr 2017).  
3.7.3 non-SiVET cohorts data 
Throughout this thesis, non-SiVET cohorts’ data will refer to data from participants in the 
observational cohorts in FF or FSW that screened failed or were not screened/recruited into SiVET 
because of SiVET sample size accrual but fulfilled the inclusion exclusion criteria in table 1.  
3.7.4 SiVET concurrent period 
Throughout this thesis, this will refer to data from both SiVET and non-SiVET cohorts (mutually 
exclusive) beginning on the date the SiVET began enrolling, and ending on the date of the last 




3.7.5 Post SiVET cohorts data  
Throughout this thesis, this will refer to all observational cohort data recorded in the twelve months 
after the final SiVET participant study visit, including new recruitments in that source population. 
3.8 Layout of the participant data used to answer PhD objectives   
Figure 8 lays out the flow of participants from observational cohorts into SiVET, non-SiVET 
cohorts in the SiVET concurrent period and post-SiVET. In addition provides reasons why 




















Fisherfolk (second cohort) 
n=575 
 
Female Sex Workers 
n=2047 
HIV incidence =4.8/100pyar HIV incidence =3.9/100pyar 
Pre SiVET period 
FF (SiVET1): Jul 2012 – Apr 2014) 
FSW (SiVET2): Aug 2014- Apr 2017 
FF: Feb 2009- Jun 2012 
FSW: Apr 2008-Jul 2014 
Fisherfolk (first cohort) 
n=1000 
HIV incidence =4.9/100pyar 
 
Enrolled in SiVET1 
(FF) n=282 
 
Enrolled in SiVET2 
(FSW) n=290 
 
SiVET Concurrent period 
 
Remained in non-SiVET1 
(FF) n=283 
 
Remained in non-SiVET2 
(FSW) n=670 
 




FF: May 2014 – Apr 2015 
FSW: May 2017 – Apr 2018 
Excluded (n=2097) 
o In OBC>18 months (n= 1871) 
o Exited OBC before SiVET (n=121) 
o HIV  positive (n=105) 
 
Excluded (n=442) 
o Withdrawn (n=74) 
o Lost (n=120) 




Table 3: Data available for answering PhD objectives, pre SiVET, SiVET concurrent and 
post-SiVET periods by population 
 
 
3.9 Answering PhD objective one 
Objective: How HIV incidence estimated from observational cohorts might differ from that in the 
HIV vaccine efficacy trials in the same population.  
Answering this was achieved by estimating and comparing HIV incidence in the SiVET cohorts 
to that in the observational cohorts pre-SiVET, in the non-SiVET cohorts in the SiVET concurrent 
period and post-SiVET cohorts (structured in figure 9 and detailed in chapter four).  
  








 FF (first cohort) FF (second cohort) 
Month of clinic visit 0 6 12 18 0 3 6 9 12 0 3 6 9 12 18 
HIV results  x x x x x x x x x x x x x x x 
 













 SiVET1 non-SiVET1 SiVET2 non-SiVET2 
Month of clinic visit  0 3 6 9 12 0 3 6 9 12 0 3 6 9 12 0 3 6 9 12 
Retention   x x x x x x x x x x x x x x x x x x x x 
HIV results  x x x x x x x x x x x x x x x x x x x x 
HIV behavioural  risk x  x  x x  x  x x  x  x x    x 
Contraceptives use x x x        x x x        
Pregnancy  x x x        x x x        









  SiVET & non-SiVET combine into 
one observational cohort  
SiVET & non-SiVET combine into 
one observational cohort 
Month of clinic visit 12 15 18 21 24 12 15 18 21 24 
HIV results x x x x x x x x x X 
*Period details are indicated in figure 9, P-Period, X-indicates procedures carried out  
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In practice, the following comparisons were made to answer PhD objective one; 
 l1 compared to l0 
 l1  compared to l2 
 l1 compared to l3 
3.9.1 Estimation of the minimum sample size needed to answer PhD objective one 
Because the primary sample size in the SiVET cohort was determined based on retention within 
12 months of follow up, a sample size needed to compare HIV incidence in SiVET cohort to 
observational cohort pre-SiVET was retrospectively estimated. To estimate this sample, the 
following assumptions were made; HIV incidence in the source population observational cohort 
of 5 per 100 person years at risk (PYAR) i.e. the average HIV incidence observed in the FF and 
FSW population in Uganda (9). Selection and HIV risk reduction measures in the SiVET would 
reduce this incidence by 40% i.e. to HIV incidence of 3 per 100 PYAR, the minimum average HIV 
incidence that would be required for a given population to qualify as a recruitment source for an 
actual HIV vaccine efficacy trial (78). Therefore, with 80% power, 5% level of significance and 
20% loss to follow up (assumed from observational cohorts in these key populations), a sample 
size of 315 participants in each of SiVETs (SiVET1 + SiVET2) and non-SiVETs cohorts would be 
sufficient to demonstrate a 40% reduction in HIV incidence.   
Observational cohorts in FF and FSW 
Application of HIV vaccine efficacy trial inclusion- 
exclusion criteria to the source observational cohort   










l2 at 12 months 
(SiVET period) 
Estimation of   
HIV Incidence 






















SiVET cohort non-SiVET cohort 
Observational cohorts  
Post-SiVET 
Estimation of   
HIV Incidence l3 




3.9.2 PhD objective one statistical analysis 
To estimate HIV incidence l0 (pre-SiVET), l1 (SiVET cohort), l2 (non-SiVET cohort), and l3 (post-
SiVET), figure 9, HIV test results data for all participants who completed at least one follow-up 
visit in a given cohort were considered. HIV incidence  was estimated as the number of HIV 
positive cases in a given period divided by the total person years at risk (PYAR) in the same period 
expressed as per 100 PYAR. PYAR were calculated as the sum of the time from the period specific 
analysis entry date to the date of the last HIV seronegative result, or to the estimated date of HIV 
infection. The date of HIV infection was defined as a random (multiple imputation) date between 
last HIV-negative and the first HIV-positive result dates. Further details are provided in the 
publication in chapter four.  
3.10 Answering PhD Objective two  
Objective: Determining uptake and use of reliable contraceptives by women participating in HIV 
vaccine efficacy trials.   
Answering this was achieved by estimating the proportion of participants that were using a reliable 
method of contraception at enrolment into SiVET and that at the end of SiVET follow up 
(structured in figure 10 and detailed in chapter five).  









In practice, the following comparisons were made to answer PhD objective two; 
 Compare p0  to p1 
 Determine correlates of reliable contraceptives use at baseline and end of follow up 
(vaccination) among women participants in the SiVET cohort.  
Application of HIV vaccine efficacy trial inclusion exclusion criteria 
to the source observational cohort    
No contraceptives 
were provided and 
no data on use of 
contraceptives 
were collected 
Estimation of the 
proportion of women (p0) 
using reliable 
contraceptives at enrolment 
into SiVET and (p1) at the 













SiVET cohort non-SiVET cohort 
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3.10.1 Estimation of the minimum sample size needed to answer PhD objective two 
It was estimated that a sample size of 366  women in the SiVETs (SiVET1  + SiVET2 ) would be 
sufficient to demonstrate an increase in reliable contraceptive to 70%  with 99% power, 5% level 
of significance and base reliable contraceptives use of 35% (observed in a cross sectional study of 
modern contraceptives use in the fishing communities, North of Lake Victoria in Uganda) (10).  
3.10.2 PhD objective two statistical analysis  
To estimate the proportion of women using reliable contraceptives at baseline p0 and that at the 
end of SiVET follow up p1, the number using reliable contraceptives at a given time point was 
divided by the total number of women enrolled and expressed as a percentage. Simple logistic 
regression models were fitted to determine baseline correlates of reliable contraceptives use at 
enrolment and at the last vaccination visit (six months of follow up). Further details are provided 
in the publication in chapter five.  
3.11 Answering PhD Objective three 
Objective: Comparing observational cohorts’ participant dropout rate to that in HIV vaccine 
efficacy trial in the same population. Answering this was achieved by estimating the rate of 
participant dropout in the non-SiVET cohort and that in the SiVET cohort in the SiVET concurrent 
period (structured in figure 11 and detailed in chapter Six).   










Application of HIV vaccine efficacy trial inclusion exclusion criteria 


















SiVET cohort non-SiVET cohort 
Estimate dropout rate (R1) 
in the SiVETs  
End of follow up  
Estimate dropout rate (R2) 











In practice, the following comparisons were made to answer PhD objective three; 
 
 
3.11.1 Estimation of the minimum sample size needed to answer PhD objective three 
It was estimated that a sample size of 324 participants in each of SiVETs (SiVET1 + SiVET2) and 
non-SiVETs cohorts would be sufficient to demonstrate a 40% decrease in dropout rate (i.e. 
dropout rate of 15 /100 PYO in SiVETs cohort) with 80 % power, 5% level of significance. Taking 
base non-SiVETs cohorts dropout rate of 25/100, PYO (observed in the fishing community 
observational cohort in Masaka, Uganda) (34).   
3.11.2 PhD objective three statistical analysis  
To estimate the dropout rate in the SiVETs (R1) and non-SiVETs (R2) cohorts, the number of cases 
(dropouts) in a given cohort were divided by total person years of observation (PYO) in the same 
cohort expressed as per 100 PYO. To determine factors associated with dropout, Poisson 
regression models were fitted for both bivariable and multivariable analyses. Similarly, further 
details are provided in the publication in chapter six.  
3.12 Answering PhD objective four  
Objective: Comparing participants HIV risk behaviours between trials and observational cohorts 
in these key populations.  
Answering this was achieved by assigning a score to each HIV risk component reported by the 
participants at baseline and at the end of follow up (structured in figure 12 and detailed in chapter 
Seven). For each participant, their composite risk score was defined as the sum of: alcohol 
consumption; use of alcohol prior to sex; number of sexual partners; starting a new sexual 
relationship recently; condom use; and presence of genital discharge and/or disease. A higher score 
indicates higher risk behaviour. The difference in this composite score between baseline and end 
of follow up (12 months) was defined as a measure of change in risk components. 
 
  
 Compare R1  to R2 














In practice, the following comparisons were made to answer PhD objective four; 
 Determine the proportion of participants with decreased risk score at the end of follow up ((S0-
S2) in the SiVETs and (S1-S3) in the non-SiVETs). 
 Compare the decrease in risk score between the SiVETs and non-SiVETs cohorts  
 Determine baseline factors associated with decrease in risk score in both SiVETs and non-
SiVETs cohorts.  
3.12.1 Estimation of the minimum sample size needed to answer PhD objective four  
Non-condom use with a new sexual or other casual partners was considered as a measure of high 
HIV risk behaviours and the following assumptions made; non-condom use in the source 
population observational cohort of 60% (27). Enrolment into SiVET would reduce this by a half 
i.e. to non-condom use of 30%. Therefore, with 80% power, 5% level of significance and 20% loss 
to follow up (assumed from observational cohorts in these key populations) (27), a sample size of 
77 participants in each of SiVETs (SiVET1 + SiVET2) and non-SiVETs cohorts would be sufficient 
to demonstrate a 50% reduction in non-condom use with a new sexual partner.    
Application of HIV vaccine efficacy trial inclusion exclusion criteria to 
the source observational cohort 
Assign a score (S1)  
to each of HIV risk 
component reported 
by each participant   
 
Assign a score (S0) 
to each of HIV risk 
component reported 
by each participant   
 














SiVET cohort non-SiVET cohort 
Month 12 Assign a score (S3)  
to each of HIV risk 
component reported 
by each participant   
Assign a score (S2)  
to each of HIV risk 
component reported 
by each participant   
 
Baseline  
End of follow up  
51 
 
3.12.2 PhD objective four statistical analysis  
Bar graphs were used to display (i) the proportion of participants reporting each risk component 
at baseline and at 12 month of follow up and (ii) the proportion of participants whose discrete 
(each variable) risk score at 12 month of follow up decreased from that reported at baseline. For 
each study participant, the composite score at baseline was subtracted from that at the end of 
follow-up to create a score difference, where a positive value indicates an increase in risky 
component and a negative value indicates a decrease. Categorized the score difference into a binary 
variable, 1 for decreased risk component (difference <0) and 0 otherwise (difference ≥0). The 
proportion of participants with decreased risk component was estimated as the number with 
difference <0 divided by the total number of participants in the analysis expressed as a percentage. 
Linear regression models were fitted stratified by the study population to determine the 
relationship of risk score at 12 months with study (non-SiVET vs SiVET) or other baseline 
participants variables adjusted for baseline risk score. After bivariable analyses, a multivariable 
model was fitted. Further details are provided in the publication in chapter seven.  
3.13 Ethical considerations  
Both the Uganda Virus Research Institute (UVRI) Research and Ethics Committee, references 
GC127, GC/127/14/04/454, GC/127/12/04/22 and GC127/12/06/01, and the Uganda National 
Council for Science and Technology, references MV834, HS364 and HS1584 approved the 
conduct of SiVETs and observational cohorts. The London School of Hygiene and Tropical 
Medicine Observational/Interventions Research Ethics Committee, reference LSHTM14588 
(appendix one) approved the concepts leading to all analyses presented in this PhD thesis. All 
participants that participated in these studies provided written informed consent before enrolment.  
We immediately referred to the local HIV treatment and care providers of their choice in the 
community for further management all participants diagnosed with HIV at screening or during 
follow up. The data used in this PhD thesis was kept with strict confidentiality. The individual 
participant unique identifiers used to link the data in the different tables during data cleaning and 





Chapter Four: How HIV incidence estimated from observational cohorts 
might differ from that in the HIV vaccine efficacy trials in the same 
population 
4.1 Research in context 
Globally, new HIV infections continue to occur most especially in Sub-Saharan Africa (SSA) 
amidst available HIV prevention interventions. In SSA, either lack of access or adherence 
problems or both have blunted the available HIV interventions. Vaccination could help minimise 
non-adherence to an HIV preventive intervention but does require the completion of the full 
vaccination schedule. The vaccines in development will have to go through assessment in efficacy 
trials. Because of the high HIV incidence, SSA will likely remain a key destination for efficacy 
trials. In Uganda, the general population HIV incidence is low; therefore, such trials will have to 
be conducted in subpopulations such as the key populations in the Fisher-folks (FF) on the 
shoreline of Lake Victoria and female sex workers (FSW) in Kampala. These two subpopulations 
are characterized by very high HIV incidence and good retention in follow up as shown in the HIV 
vaccine preparedness observational cohorts conducted by the International AIDS vaccine Initiative 
(IAVI) and its partners in Africa. 
4.2 HIV incidence in Efficacy Trials  
Designing the intended HIV vaccine efficacy trials in the FF and FSW populations will require an 
accurate estimate of the HIV incidence in the control (placebo) arm. To achieve this, the common 
practice is that investigators use HIV incidence from the control (placebo) arms of previous 
efficacy trials in the same or similar populations. Unfortunately, to date no HIV vaccine efficacy 
trials have been conducted in the FF or FSW populations in Uganda. Where such data is not 
available, HIV incidence from historical or pilot cohorts can fill the void. Therefore, the HIV 
incidence estimated in the IAVI and its partners’ HIV vaccine preparedness cohorts in the FF and 
FSW can be used. 
4.3 Pitfalls in estimating HIV incidence in trials  
The available evidence shows that participants who join efficacy trials may have a different HIV 
incidence from that estimated in the observational cohorts because the trial environment is highly 
controlled.  A systematic review, Padian NS et al 2010, published in AIDS journal identified six 
HIV prevention trials that were unsuccessful and/or terminated before end of participants follow 
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up due to observing lower HIV incidence during participant follow up than that obtained from 
underlying observational cohort data. Furthermore, three microbicides trials (two by Peterson et al 
2007 published in PloS one and Plos clinical trials, and one by Feldblum PJ et al, 2008 in PloS 
one) in West Africa were planned assuming placebo arm HIV incidence of 5 per 100 person years 
at risk (pyar) derived from observational data. The three trials were prematurely terminated after 
all of them had observed less than half the assumed HIV incidence. On the contrary, a recent 
dapivirine ring trial, Baeten et al, 2016 in South Africa published in the New England Journal of 
Medicine assumed HIV incidence of 3.9 per100 pyar in the control arm.  HIV incidence of 5 per 
100 pyar was observed during participant follow up and the sample size was recalculated assuming 
the new observed incidence. At the end of the trial follow up, HIV incidence of 4.5 per 100pyar 
was observed in the control (placebo) arm.  The discrepancies between the assumed and observed 
HIV incidence show that while planning HIV vaccine efficacy trials, observational data need to be 
used with caution.  
4.4 Trials simulating HIV vaccine efficacy trials to estimate incidence  
IAVI and its African partners have conducted two Simulated HIV Vaccine Efficacy Trials 
(SiVETs), mimicking an HIV vaccine efficacy trial conducted with a Hepatitis B vaccine (a 
commercially licensed vaccine with potential benefit for participants) to simulate the procedures 
and schedule of an HIV vaccine efficacy trial, with full knowledge of participants. SiVETs were 
nested in longitudinal observational cohorts in the FF and FSW populations in Uganda. The proxy 
vaccine used here was not expected to have any effect on the risk of HIV infection but to provide 
a trial environment similar to the placebo arm of an actual HIV vaccine trial in these populations.  
4.5 Data to answer PhD Objective one   
Data from SiVETs and observational cohorts were used to answer the PhD objective one i.e.  
Comparing HIV incidence in SiVETs to that in the observational cohorts, in the pre-SiVET, the 
concurrent non-SiVET cohort, and post SiVETs periods. This aimed at investigating how HIV 




4.6 Key findings  
Overall, the HIV incidence in the SiVETs of 3.5 per 100 person years at risk (PYAR), 95% Cl: 2.2 
- 5.6 was lower than 4.5 per 100 PYAR, 95% Cl: 3.8 - 5.5 in the source observational cohorts pre-
SiVET and 5.9 per 100 PYAR, 95% Cl: 4.3 - 8.1 in the concurrent non-SiVET cohort. The HIV 
incidence in the post-SiVETs observational cohorts of 3.7 per 100 PYAR, 95% Cl: 2.5 - 5.8 was 
similar to that in the SiVETs. The same pattern (differences in HIV incidence between SiVET and 
observational cohort) was observed in the FF and FSW populations, with a greater difference in 
the population of Fisher-folk. Additionally, participants who joined SiVETs differed in important 
ways from those who did not. Furthermore, HIV incidence varied by the different participant 



































Supplementary, Table 4: HIV incidence by cohorts’ participant characteristics in the three 
periods not stratified by population  
Variables          Period (i)  Period (ii)  
 
    Period (iii) 
 Non-SiVET data  
 

















Sex          
 Male  38/773.0 4.9 (3.6-6.8) 8/138.9 5.8 (2.9-11.5) 7/193.1 3.6 (1.7-7.6) 6/206.2 2.9 (1.3-6.5) 
 Female  67/1536.7 4.4 (3.4-5.5) 31/519.2 6.0 (4.2-8.5) 10/291.8 3.4 (1.8-6.4) 15/351.1 4.3 (2.6-7.1) 
Age group (years)         
 18-24 44/823.8 5.3 (4.0-7.2) 13/291.1 4.5 (2.6-7.7) 6/141.6 4.2 (1.9-9.4) 5/209.4 2.4 (1.0-5.7) 
 25-34 48/1040.7 4.6 (3.5-6.1) 18/276.2 6.5 (4.1-10.3) 8/226.5 3.5 (1.8-7.1) 8/247.0 3.2 (1.6-6.5) 
 35+ 13/445.2 2.9 (1.7-5.0) 8/90.8 8.8 (4.4-17.6) 3/116.8 2.6 (0.8-8.0) 8/101.0 7.9 (4.0-15.8) 
Tribe         
 Baganda 48/1101.0 4.4 (3.3-5.8) 15/274.6 5.5 (3.3-9.0) 6/235.6 2.5 (1.1-5.7) 6/271.3 2.2 (1.0-4.9) 
 Banyankole 14/274.4 5.1 (3.0-8.6) 7/118.5 5.9 (2.8-12.4) 5/53.0 9.4 (3.9-22.6) 3/73.2 4.1 (1.3-12.7) 
 Banyarwanda 18/278.8 6.5 (4.1-10.2) 7/94.7 7.4 (3.5-15.5) 3/68.5 4.4 (1.4-13.6) 3/81.3 3.7 (1.2-11.4) 
 Other  22/653.6 3.4 (2.2-5.1) 10/170.2 5.9 (3.2-10.9) 3/127.7 2.4 (0.8-7.3) 9/130.6 6.9 (3.6-13.2) 
Education         
 None 19/512.7 3.7 (2.4-5.8) 10/176.0 5.7 (3.1-10.6) 2/29.7 6.7 (1.7-26.9) 6/117.4 5.1 (2.3-11.4) 
 Primary  63/1252.0 5.0 (3.9-6.4) 19/347.1 5.5 (3.5-8.6) 10/312.8 3.2 (1.7-5.9) 10/330.3 3.0 (1.6-5.6) 
 Secondary+ 23/545.0 4.2 (2.8-6.4) 10/135.0 7.4 (4.0-13.8) 5/142.4 3.5 (1.5-8.4) 5/109.7 4.6 (1.9-11.0) 
Marital status         
 Single never 
married 
29/549.3 5.3 (3.7-7.6) 8/210.1 3.8 (1.9-7.6) 7/132.5 5.3 (2.5-11.1) 4/167.7 2.4 (0.9-6.4) 
 Married 44/968.1 4.5 (3.4-6.1) 12/156.7 7.7 (4.4-13.5) 4/146.0 2.7 (1.0-7.3) 4/169.4 2.4 (0.9-6.3) 
 Single ever 
married 
32/792.3 4.0 (2.9-5.7) 19/291.3 6.5 (4.2-10.2) 6/206.5  2.9 (1.3-6.5) 13/220.2 5.9 (3.4-10.2) 
Religion          
 Christian  83/1789.4 4.6 (3.7-5.8) 29/478.2 6.1 (4.2-8.7) 10/370.6 2.7 (1.5-5.0) 16/418.0 3.8 (2.3-6.2) 
 Muslim  22/520.3 4.2 (2.8-6.4) 10/180.0 5.5 (3.0-10.3) 7/114.3 6.1 (2.9-12.9) 5/139.4 3.6 (1.5-8.6) 
Occupation         
 Fishing/fish 
related   
26/486.7 5.3 (3.6-7.8) 7/129.6 5.4 (2.6-11.3) 6/158.5 3.8 (1.7-8.4) 7/181.7 3.9 (1.8-8.1) 
 Small scale 
business 
21/531.6 3.9 (2.6-6.1) 8/80.4 9.9 (5.0-19.9) 3/77.5 3.9 (1.2-12.0) 1/69.2 1.5 (0.2-10.3) 
 Hotel/Bar/Hair 
saloon 
29/559.0 5.2 (3.6-7.5) 8/159.9 5.0 (2.5-10.0) 6/107.0 5.6 (2.5-12.5) 2/98.4 2.0 (0.5-8.1) 
 Sex work 17/352.4 4.8 (3.0-7.8) 13/238.1  5.5 (3.2-9.4) 2/123.6 1.6 (0.4-6.5) 8/171.8 4.7 (2.3-9.3) 
 Other  12/380.0 3.2 (1.8-5.6) 3/50.0 6.0 (1.9-18.6) 0/18.3 - 3/36.3 8.3 (2.7-25.7) 
Duration lived at the current location (years)       
 0-1  33/541.8 6.1 (4.3-8.6) 14/200.3 7.0 (4.1-11.8) 6/76.9 7.8 (3.5-17.4) 6/134.7 4.5 (2.0-9.9) 
 >1  72/1767.8 4.1 (3.2-5.1) 25/457.8 5.5 (3.7-8.1) 11/408.0 2.7 (1.5-4.9) 15/422.7 3.5 (2.1-5.9) 
Illicit drug use         
 No  86/1846.0 4.7 (3.8-5.8) 25/321.3 7.8 (5.3-11.5) 9/271.5 3.3 (1.7-6.4) 1/45.1 2.2 (0.3-16.5) 
 Yes  19/463.7 4.1 (2.6-6.4) 14/336.9 4.2 (2.5-7.0) 8/213.4 3.7 (1.9-7.5) 20/512.3 4.1 (2.7-6.3) 






Chapter five: Determining uptake and use of reliable contraceptives by women 
participating in HIV vaccine efficacy trials 
 
5.1 Research in context  
Sub-Saharan Africa (SSA) suffers the highest burden of HIV. Some sub-populations, such as 
members of fishing communities, fisher-folks (FF) and female sex workers (FSW), are 
disproportionately affected. Because of the high HIV incidence, these communities are attractive 
for the conduct of HIV vaccine efficacy trials. However, such trials could take months or years 
from recruitment to completion. In this long period, women could become pregnant and might 
have to be withdrawn from follow up due to unknown effects of the new investigational product 
on the foetus. More withdrawals than that anticipated could have negative effects on the trial 
statistical power. To avoid pregnancy in trials, women are required to take up and adhere to use of 
reliable, long-acting, reversible contraceptive methods. The common practice is to exclude women 
not agreeing to reliable contraceptive use during follow up. Such exclusion could introduce 
selection bias. Many women in SSA do not use contraceptive methods because of lack of access 
or misconceptions about contraceptives. Supporting women’s use of reliable contraceptives, helps 
to avoid selection bias at enrolment and a loss of statistical power by limiting the risk of unintended 
pregnancies leading to withdrawals during participant follow up in efficacy trials.  
5.2 Contraceptives data for planning efficacy trials (common practices) 
To prevent pregnancy in HIV vaccine efficacy trials anticipated, use of reliable contraceptives has 
become a key inclusion criterion. Data on reliable contraceptives use for planning such efficacy 
trials come from previous trials in the same or similar populations. Completed HIV vaccine 
efficacy trials have shown that one third of the enrolled women were already using a reliable 
method of contraceptives at baseline but did not indicate any data on uptake during follow up. The 
annual incidence of pregnancy was high, 9.6 per 100 women years of follow up. This data come 
from trials conducted in the general population but key populations tend to be special populations.  
In populations where no trial specific context data exist such as Fisher-folks on the shoreline of 
Lake Victoria and Female Sex Workers in Kampala Uganda, the common practice is prospective 
trial participants may be required to use reliable contraceptive methods for ≥3 months before 
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screening and enrolment. This increases the cost of conducting trials and delays rollout, but avoids 
costly drop out from trials due to non-compliance. 
As indicated in chapter four (section 4.4), SiVET concept was used to investigate reliable 
contraceptive use among women Fisher-folks and Female sex workers during two Simulated HIV 
Vaccine Efficacy trials in Uganda.   
5.3 Key findings  
Overall, the promotion and provision of reliable contraceptive methods in the SiVET improved 
their use from one in every two women at baseline to nine in every 10 women at the end of the 
vaccination schedule follow up.  Secondly, the use of reliable contraceptives methods at baseline 
was particularly higher among young women and illicit drug users. Similarly, young women, those 
with secondary or more education and the FSW population used reliable contraceptives more than 
their counterparts did by end of vaccination. Promotion and provision of reliable contraceptives to 
women not using them at baseline improved the proportion using them mainly within the first 
month of follow up. A low proportion of participants, 3% got pregnant during follow up. Further 
details are provided in the publication below.  
5.4 Implications for future HIV vaccine efficacy trials in these key populations  
Promotion and provision of reliable contraceptives in these key populations leads to high uptake 
and use, and lowers the incidence of pregnancy. Investigators planning HIV vaccine efficacy trials 
in these and similar populations may not need to put women volunteers on reliable contraceptives 
for atleast three months before screening and enrollment. Provision of reliable contraceptives as 







































Chapter Six: Comparison of retention in observational cohorts and nested 
Simulated HIV Vaccine Efficacy Trials in the Key populations in Uganda  
 
6.1 Research in context  
Global estimates show that 65% of new HIV-infections occur in Sub-Saharan Africa (SSA) in 
presence of available HIV prevention interventions, but poor adherence to the interventions limit 
their effectiveness (5). Vaccination is an intervention that does not rely on individual adherence 
but does require the completion of the full vaccination schedule. Because of the high HIV 
incidence in SSA, an affordable HIV vaccine is urgently needed, and SSA would be a key 
destination for HIV vaccine efficacy trials. In Uganda, these trials can be conducted in the 
population subgroups such as fisher-folks and Female sex workers, but these groups are very 
mobile. There are still methodological issues on the best way to measure retention in efficacy trial 
especially in subpopulations where no such trials have been previously conducted.  Available data 
on retention come from observational cohorts, but participants that join trials might have different 
retention to the observational cohorts they are drawn from. Therefore, extrapolating the retention 
of an observational cohort to the planning of HIV vaccine efficacy trial may be complicated. An 
under or over estimation of the number expected to complete follow up could affect the trial 
statistical power or expose more participants than necessary to an investigational product with 
unknown effects.    
6.2 Trials simulating HIV vaccine efficacy trials to estimate retention  
Data from two Simulated HIV Vaccine Efficacy Trials (SiVETs) that mimicked an HIV vaccine 
efficacy trial conducted with Hepatitis B vaccine (a commercially licensed vaccine with potential 
benefit for participants) with full knowledge of the participants was used to answer this objective. 
The SiVETs were nested within observational cohorts of Female Sex Workers (FSW) and Fisher-
folks (FF) subpopulations in Uganda, enabling estimates of participant dropout, in order to provide 
accurate data needed to plan future HIV vaccine efficacy trial in these key populations. To answer 
PhD objective 3, dropout rate in observational cohorts was compared to that in the nested 
Simulated HIV Vaccine Efficacy Trials in the same population of FF or FSW in Uganda. Further 
details are provided in the publication below.   
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6.3 Results of alternative approach using time to event analysis  














Figure 13 shows a Kaplan-Meier plot of the time to dropout analysis stratified by non-SiVET and 
SiVET cohorts. The results of a survival analysis are shown in the same figure including the results 
of fitting a Cox regression model comparing between the two cohorts. The stratified log-rank test 
provided strong evidence that the risk of dropping out of studies was higher in the non-SiVET 
cohort than in the SiVET cohort , log-rank test; χ2 = 10.49; (P = 0.0012). This was confirmed by 
the results of the Cox regression model: hazard ratio (HR); 0.68 (95% Cl: 0.53-0.86), p=0.002.  
From the same figure, it can be deduced that a higher number of participants dropped out of the 
cohorts at enrolment and towards the end of follow up with greater dropouts in the non-SiVET 
cohort.  
6.4 Keys findings  
Overall, results suggest that the annual dropout rate in the SiVETs of 18.4 per 100 person years of 
observation (PYO), 95%Cl: 15.1 - 22.4 was lower than 31.6 per 100 PYO, 95%Cl: 27.8 - 36.1  in 
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observational cohort was generally similar, the actual dropout rates were higher in the FSW 
population.  
6.5 Implications for anticipated HIV vaccine efficacy trials in these key populations  
Conduct of SiVETs in these key populations could mean that designing HIV Vaccine Efficacy 
Trials will benefit from relative lower dropout rate shown in SiVET than source observational 
cohort. In absence of the SiVETs conducted in these key populations, the trial sample size would 
be adjusted by a higher dropout rate observed in the source observational cohort. This could lead 
to exposing more participants to a new investigational product than necessary. In similar 
populations where no previous HIV prevention trials or SiVETs have been conducted, to provide 
information on dropout, observational cohorts’ data on dropout rate might be useful but this will 



















































Chapter Seven: Comparison of HIV risk behaviours between clinical Trials and 
observational cohorts in Uganda  
7.1 Research in context 
Key populations such as Fisher-folks (FF) on the shoreline of Lake Victoria and female sex 
workers (FSW) in Kampala, Uganda have higher HIV risk behaviours, hence higher HIV incidence 
than the general populations (23, 25, 27). This makes them attractive for the conduct of anticipated 
HIV vaccine efficacy trials. However, no HIV prevention trials have been conducted in these key 
populations to provide trial specific context baseline data. Available information on trial targeted 
outcomes in these key populations come from observational cohorts. Previous HIV prevention 
trials have shown lower HIV incidence during participant follow up in trials compared to that 
obtained from the underlying observational cohort data from the same populations prior to the trial 
onset. Some of these trials were prematurely terminated due to loss of statistical power (38, 39, 
42). One of the key reasons advanced for the diminished HIV incidence was that participants had 
lower HIV risk behaviours due to rigorous HIV risk-reduction measures in trials (38). Participants 
that joined the trials reported higher increases in condom use, fewer numbers of sexual partners 
and fewer sex acts compared to the baseline.  
7.2 Trials Simulating HIV vaccine efficacy trials in FF and FSW in Uganda 
Two Simulated HIV Vaccine Efficacy Trials (SiVETs) nested within observational cohorts of 
Female Sex Workers and Fisher-folks subpopulations in Uganda were conducted and are  
described in previous chapters of this thesis. The data from these SiVETs were used to estimate 
participant response to HIV risk reduction measures by way of comparing HIV risk behaviours at 
baseline and at the end of follow up. These were further compared between the observational 
cohort and the nested simulation trial in the same population. The detailed methods and results are 
provided in the manuscript draft below.   
7.3 Key findings  
Results suggest that in both SiVETs and source observational cohorts, the proportion of 
participants with high-risk HIV behaviour decreased over the one-year follow-up with greater 
decreases in SiVETs. Overall, 72.2% (95% Cl: 68.0% - 76.0%) of the participants in SiVETs 
experienced a decrease in high-risk behaviour compared to 54.0% (95% Cl: 50.1% - 57.8%)  in 
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the source observational cohorts. The decrease in high-risk behaviour was lower among Female 
Sex Workers than Fisher-folks; conversely, the difference between SiVET and source 
observational cohort was greatest in the FSW population. Further details are indicated in the 
publication below.  
7.4 Implications for anticipated HIV vaccine efficacy trial in these key populations 
Conduct of SiVETs in these key populations could mean that investigators recruiting participants 
into clinical trials from observational cohorts in these or similar populations need to consider the 














































Chapter 8: Discussion  
8.1 Introduction  
The planning of HIV vaccine efficacy trials in the fisher-folk (FF) and female sex workers (FSW) 
populations  in Uganda will require accurate estimation of the trial targeted outcome components 
and other key elements. These will include  (a) HIV incidence in the control (placebo) arm, (b) 
retention, (c) reliable contraceptives use to prevent pregnancy  and (d) the expected reduction in 
HIV incidence due to vaccination (treatment effect). This thesis covers components/elements (a) 
to (c). The common practice (source of these components/elements) includes adopting these from 
previous efficacy trials in the target population.  
8.2 Estimation of HIV efficacy trial control arm HIV incidence in FF or FSW in Uganda 
To date, no HIV vaccine efficacy or other prevention trials have completed follow up in the FF on 
the shore of Lake Victoria or FSW population in Kampala, Uganda. Therefore, data on assumed 
HIV incidence in the control arm of anticipated HIV vaccine efficacy trial will have to come from  
historical observational or pilot cohorts in these key populations.  
8.3 Challenges of using observational studies HIV incidence to plan efficacy trials  
Extrapolation of observational data to plan efficacy trials is complicated and needs to be done with 
caution to minimize selection bias. Observational data on HIV incidence may not accurately 
estimate that in an efficacy trial because of the differences in selection criteria and the highly 
controlled trial environment. Efficacy trials select participants who fulfill the trial inclusion criteria 
including among others; willingness to attend all trial clinic visits, if female accepting reliable 
contraceptives use in the duration of follow, and  conforming to the use of HIV risk reduction 
measures provided. Such selection requirement many include into trial participants with HIV risk 
profile different from those excluded. This may affect HIV incidence in the trial adopted from 
observational data, even in absence of an effective investigational product.  
8.4 Simulated vaccine efficacy trials  
A simulated vaccine efficacy trial is a trial which mimics an actual efficacy trial but uses a 
commercially licensed vaccine instead of an experimental one. It is  conducted in the same manner 
as an actual efficacy trial in all other respects. The concept of simulation trials  has been previously 
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used in a population where no baseline data was available to aid planning of trials (67). Similarly, 
this concept was used in the FF and FSW populations in Uganda, primarily to provide accurate 
data on participant retention in a vaccine efficacy trial specific context. Data from these simulation 
trials was used to investigate these PhD questions/objectives. (a) how HIV incidence in a 
simulation trial might differ from that in observational cohorts, in which the trials were nested in 
the FF and FSW populations in Uganda, (b) use of reliable contraceptives by female participants, 
(c) participant retention in follow up and (d) participant response to other HIV risk reduction 
measures. 
8.5 HIV incidence in vaccine efficacy trials in FF and FSW in Uganda 
The first key step in planning HIV vaccine efficacy trial in these populations is accurate estimation 
of HIV incidence in the control (placebo) arm. To provide such data for FF on the shoreline of 
Lake Victoria and FSW in Kampala, Uganda, the HIV incidence observed in simulation trials was 
compared to that seen in observational cohorts in the same population in the three time periods: 
pre-trial, concurrent, and post-trial. Results suggested that HIV incidence in the simulation trials 
was lower than that in the observational cohorts in the pre-trials and the trials concurrent period 
but tended to be similar to that in the observational cohorts in the 12 months post-trials period.   
Table 5: HIV incidence pre, during and post simulation trial and stratified by the study population  







Observational  data  Simulation trials data   
Incidence (95%CI) 
 





Fisher-folk 4.9 (3.9-6.2)  8.3 (5.6-12.4)  3.8 (2.0-7.1)  4.1 (2.3-7.3) 
FSW 4.0 (2.9-5.5)  4.1 (2.5-6.7)  3.2 (1.5-6.6)  3.4 (1.8-6.5) 
Overall 4.5 (3.8-5.5)  5.9 (4.3-8.1)  3.5 (2.2-5.6)  3.7 (2.5-5.8) 
FSW: Female sex work, CI: Confidence Interval  
The difference in HIV incidence between the source observational cohort and simulation trial was 
highest in the Fisher-folks population.  
8.6 Likely reasons for lower incidence in the simulation trials  
The reasons for the lower incidence in the Simulation trial as opposed to observational studies 
could be (1) selection differences at enrolment,  (2) different environment in that the trial 
encouraged the participants to engage in HIV prevention, (3) follow-up differentials (retention), 
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and (4) Chance (not covered in this thesis). These may not be mutually exclusive. The reasons (1-
3) correspond to the three papers presented in chapters 4, 6 and 7.  
8.6.1 Selection differences at enrolment 
Results in these papers suggest differences in the participants’ characteristics between those who 
joined the simulation trials and those that did not. The observational cohorts in FF and FSW 
populations were the participants’ recruitment source for the simulation trials in these key 
populations, however, participants that entered trials differed from those that did not in some 
important ways. The proportions of participants with characteristics (male (FF only), age >25 
years, with some formal education and more than one year in community) previously associated 
with lower risk of HIV acquisition (27, 28, 30, 66, 79-82) were higher in the simulation trials. The 
differences in volunteer characteristics between clinical trials and source populations and their 
effect on HIV incidence are previously highlighted (39, 64).  
8.6.2 Trial environment  
Reduction in HIV incidence in the trials could also be attributed to the controlled environment of 
the trial. This has previously been associated with more than a 50% reduction (from that seen in 
the underlying cohort) in HIV incidence in the control arm during follow up (38, 39, 42). These 
trials were prematurely terminated. The investigators attributed the reduction in incidence to 
participants’ vigorous response to HIV risk reduction measures and inclination to safer HIV risk 
behaviours during follow up. In our simulation trials, we provided a wide range of HIV risk 
reduction measures including HIV counseling and testing, counselling on concurrent multiple 
sexual partners, condom use, faithfulness to one partner, provided free condoms, actively 
diagnosed and treated sexually transmitted and other genital infections. While participants in the 
observational cohorts also received these interventions, the frequency of their provision was lower, 
they only received condoms on request and no active diagnosis and treatment for STIs and other 
genital infections was done. As presented in chapter 7, we observed greater decreases in HIV risk 
behaviours in the simulation trials compared to observational cohorts in both key populations. 
These HIV risk reduction measures, when applied to an HIV vaccine efficacy trial planned in these 
key populations, could lower the risk of HIV infection during participant follow up even in the 
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absence of an effective HIV vaccine. If their effect on HIV incidence is not carefully adjusted for 
at the trial planning stage, it could diminish statistical power.   
8.6.3 Follow up differentials  (retention)  
Our simulation trials aimed at providing context-specific information on trial dropout for FF and 
FSW populations. In these simulation trials, we found that the dropout rate in the trials was nearly 
half that in the source observational cohorts in the same population and aligned to the same 
duration. The lower dropout rate in the trials could be attributed to the enhanced follow up 
procedures. Simulation trials participants were reminded of their next scheduled clinic visit at least 
two days in advance, and were picked up by a trial staff on a motor cycle or vehicle if they needed 
help to access the clinic for their visits. Such strategies in trials have been previously associated 
with high retention during follow up among the Fisher-folks (83) and other populations (84). 
Furthermore, Literature shows that participants at higher risk of HIV infection are also more likely 
to dropout of longitudinal studies which could lead to inaccurate estimation of HIV incidence in 
the underying population (33, 85).  
Similar differences in dropout between non-SiVET and SiVET were observed when the analysis 
considered time to dropout approach.  The plot of a Kaplan Meier gave extra evidence that most 
of the study participant dropout happened either early in the study or later on during follow up. 
Early dropout from the study could affect study internal validity and factors leading to early or 
mid-study dropout might be different from those associated with late dropout. Early study dropout 
(baseline dropout) may be associated with a  passive resistance to participation by those who find 
it difficult to refuse outright. On the otherhand, late study attrition may be associated with 
individual participant experiences with the study including among others having suffered an 
adverse event. Both early and late dropout negatively affect the trial statistical power. Either stage 
of trial dropout could led to having lower number of person time of follow up required to evaluate 
the treatment effects between active and control arms with greater effects linked to early dropout.  
8.6.4 Access to pre exposure prophylaxis (PrEP)  
PrEP is new HIV prevention modality that is now a standard part of HIV prevention trials. We 
were not able to assess PrEP access in the SiVETs and it is unlikely that participants in these 
communities accessed PrEP. PrEP provision in HIV vaccine efficacy trials anticipated in these 
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communities will likely further push HIV incidence rates down, calling for increases in the trial 
size. Given how compliance with PrEP has been so problematic (86), it is unclear how much HIV 
incidence might drop (i.e., how good PrEP uptake and compliance will be); some PrEP trials (87) 
and programmes (88-90) have shown very high compliance with PrEP being associated with  HIV 
incidence rates plummeting. Figuring out how to implement this in the African context 
(specifically among FF and FSW), would certainly impact trial size and planning. 
8.7 Impact of these findings on planning for an HIV vaccine efficacy trial  
Putting the observed results in the context of an actual HIV vaccine efficacy trial, the results overall 
suggested that using HIV incidence and retention from observational studies to plan an HIV 
vaccine efficacy trial as opposed to using simulation trial incidence and retention would 
underestimate the trial sample size by about one-quarter and achieve a statistical power of 68%. 
When stratified by the source population, the underestimation of the study size was highest in the 
Fisher-folk population. The simulation trials in both key populations provided a benchmark HIV 
incidence and retention that could be a useful aid when planning HIV vaccine efficacy trials in 
these and similar populations.  
8.8 Reliable contraceptives use  
The other key element in planning HIV vaccine efficacy trial is the adequate use of reliable 
contraceptives by female participants to avoid pregnancy during follow up. HIV vaccine efficacy 
trials take months from recruitment to completion of follow up and women could become pregnant 
and have to withdraw. More withdrawals than anticipated could affect trial statistical power. Use 
of reliable contraceptives in trials to prevent the foetus from exposure to investigational products 
whose effects are unknown has become a key inclusion criterion (61). This requirement could 
make it difficult to recruit women into HIV vaccine efficacy trials in FF and FSW populations 
because of cultural beliefs and myth about contraceptives in Africa (91-99).   
Completed HIV vaccine efficacy trials have shown low baseline reliable contraceptives use with 
limited data on uptake during follow up and high incidence of pregnancy (55). In these simulation 
trials in the FF and FSW in Uganda, we found  that only one in every two women were using a 
reliable contraceptives method at baseline, and this improved to nine in every ten women at the 
end of follow up as a result of promotion and provision of reliable methods. Acceptance to use of 
119 
 
reliable contraceptives was a key inclusion criterion in our simulation trials unlike in previous HIV 
vaccine efficacy trials. Furthermore, in the FSW population, pregnancy affects the source of 
livelihood hence the huge motivation to use reliable contraceptives beyond that seen in the fisher-
folks or previous trials that recruited women from the general population.   
There is a perception that women in these key population may be difficult to recruit into 
longitudinal studies where use of reliable contraceptives is key (100, 101). However, in our 
SiVETs, 80% of the screened women were enrolled and only under 2% of the women were 
excluded because of unwillingness to use a reliable contraceptive method. Accurate messaging 
and meeting the unmet need of contraceptives in these key populations could have played a role. 
Accurate information about contraception has been associated with improved contraceptives 
uptake in the previous HIV prevention trial recruiting HIV serodiscordant couples (51). More 
interesting, we are only aware of  eleven women who became pregnant during follow up and seven 
of these were on reliable contraceptive methods. Four of the seven were on injectable DMPA and 
had delayed an injection by about a month; while three used pills. The challenge with use of pills 
in trials is previously documented (102). In these previous trials, women using pills had a 
pregnancy rate more than three times higher than average, mainly attributed to poor adherence.   
8.9 Study strengths  
Strengths of this study include: large sample sizes; two distinct key populations in different 
geographical locations; aligning both the simulation trial and observational cohort to the same 
duration of follow up in a concurrent period; and same study staff attending to the participants in 
both studies (simulation trial and source observational cohort in a given population).  Additionally, 
promotion and provision of reliable contraceptives in the context of HIV vaccine efficacy trial, 
counselling women on the importance of reliable contraceptives use and providing them with a 
method of their choice. Lastly, we allowed a run-in period of at least three months participation in 
the source cohort mimicking a screening enrolment time lag in an actual HIV vaccine efficacy 
trial.  
8.10 Study limitations  
Although HIV vaccine efficacy trials in these key populations will be expected to have a 
participant run in period, it might not be up to three months. Selection bias (inform of self-selection 
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or the study teams recruiting into the simulation trials mostly participants that came on time for 
their source observational cohort visits) could have played a role in the participant recruitment. 
This could have led to selection of participants mostly from low HIV risk groups such as long-
term residents and those easier to keep in follow up. Even then, actual HIV vaccine efficacy trials 
anticipated in these populations are expected to recruit participants that confirm availability for 
follow up in the trial duration and presenting for recruitment in a given screening-enrolment 
window period when results of screening are still valid. Simulation trials participants were fully 
informed that the vaccine being administered has no effect on their risk of HIV infection but 
prevented acquisition of hepatitis B virus. This could have enhanced continued trial attendance in 
a country where the burden of Hepatitis B is high (103). Nonetheless, in an actual HIV vaccine 
efficacy trial, participants are expected to be informed of accurate information about the candidate 
product. Notwithstanding these limitations, these studies provided for the first time a rare 
opportunity for estimating HIV vaccine efficacy trial targeted outcomes in a trial specific context 
in two distinct key populations in Uganda. 
8.11 Conclusion  
In summary, we observed in our cohorts that individuals in FF and FSW populations that volunteer 
to join trials are different from those that do not. This difference together with trial environment 
lead to lower HIV incidence in the trials even in absence of an effective investigational product. 
Promotion and provision of reliable contraceptives and counselling on their use more than double 
the proportions of women using them during trial follow up from that recorded at baseline. 
Enhanced retention strategies improve retention of volunteers in these highly mobile populations. 
Lastly, HIV risk reduction measures provided in the simulation trials decreased the proportion of 
participants engaging in high HIV risk behaviours. Interestingly, the HIV incidence in these key 
populations remains high, in an era of wide spread use of antiretroviral treatment, and while 
reduced in the simulation trials, it is still suitable for actual HIV vaccine efficacy and other 
intervention trials in these and similar key populations. 
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8.12 Recommendations  
 HIV incidence  and dropout in the SiVETs in these and similar key populations where no 
previous efficacy trials have been conducted should be used to estimate sample size for 
future HIV vaccine efficacy trials. 
 In similar populations where there is no SiVET data or data from previous efficacy trials, 
we recommend use of observed incidence and dropout in observational data but decreasing 
this incidence and dropout by 25% and 40% respectively to accommodate for the likely 
lower incidence and dropout in trials.  
 To improve study completion in these populations, an investigator needs a phone contact 
of a participant’s neighbor or someone that knows about a participant’s whereabout at all 
times. This will help to improve participant tracing.  
 Helping participants to access the trial clinic by way of providing physical transport using 
motor cycle or motor vehicle will improve trial completion in these key populations.  
 We recommend use of FF and FSW populations in Uganda as source populations for HIV 
vaccine and other efficacy trials targeting women because of the high screening-enrolment 
ratio, high reliable contraceptives uptake and use, and low pregnancy incidence.  
 In the FF and FSW and similar key populations, it is not necessary to put women on reliable 
contraceptives for atleast three months before screening for trial enrolment instead these 
should happen concurrently.  
8.13 Future work 
Further work planned in these observational cohorts and SiVETs includes using propensity score 
matching to segregate the effect of the difference in participant characteristics between SiVET and 
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